Sign up to save your podcasts
Or
Share Pfizer’s Q3 Earnings Win, Deals Galore, Countdown to Election, More
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Pfizer’s Q3 Earnings Win, Deals Galore, Countdown to Election, More
Earnings heat up as Pfizer got a much-needed Q3 beat amidst criticism from activist investor Starboard Value. Novartis and Sanofi are among others that have outpaced Wall Street expectations this quarter, as Eli Lilly, Merck, AbbVie, Amgen, Biogen, GSK, Bristol Myers Squibb and Takeda are all reporting today and tomorrow.
The past week has also seen a pack of deals, with AbbVie’s $1.4 billion buy of Aliada Therapeutics, Roche’s potential $1 billion deal with Dyno Therapeutics
and Novartis’ up to $2.1 billion commitment to Monte Rosa’s molecular glue degraders.
With less than a week until Election Day, we unpack
what biopharma might expect under a Trump or Harris administration. We also take a look back at 10 years of BioSpace’s NextGen list of top up-and-coming startups. A lot have been bought out by bigger companies—some for big money—while some, such as CRISPR Therapeutics, continue to operate independently.
Finally, we took a close look at questions stemming from Sarepta’s new data for Duchenne muscular dystrophy gene therapy Elevidys, and separately but not unrelatedly, at the FDA’s accelerated approval pathway.
View all episodes
By BioSpace
4.9
1313 ratings
Earnings heat up as Pfizer got a much-needed Q3 beat amidst criticism from activist investor Starboard Value. Novartis and Sanofi are among others that have outpaced Wall Street expectations this quarter, as Eli Lilly, Merck, AbbVie, Amgen, Biogen, GSK, Bristol Myers Squibb and Takeda are all reporting today and tomorrow.
The past week has also seen a pack of deals, with AbbVie’s $1.4 billion buy of Aliada Therapeutics, Roche’s potential $1 billion deal with Dyno Therapeutics
and Novartis’ up to $2.1 billion commitment to Monte Rosa’s molecular glue degraders.
With less than a week until Election Day, we unpack
what biopharma might expect under a Trump or Harris administration. We also take a look back at 10 years of BioSpace’s NextGen list of top up-and-coming startups. A lot have been bought out by bigger companies—some for big money—while some, such as CRISPR Therapeutics, continue to operate independently.
Finally, we took a close look at questions stemming from Sarepta’s new data for Duchenne muscular dystrophy gene therapy Elevidys, and separately but not unrelatedly, at the FDA’s accelerated approval pathway.
More shows like BioSpace
View all
This American Life
91,165 Listeners
Planet Money
30,719 Listeners
Hidden Brain
43,569 Listeners
Marketplace
8,784 Listeners
Exchanges
975 Listeners
WSJ What’s News
4,391 Listeners
Bloomberg Surveillance
1,175 Listeners
Odd Lots
1,986 Listeners
Up First from NPR
56,892 Listeners
The Indicator from Planet Money
9,559 Listeners
The Readout Loud
337 Listeners
The Journal.
6,135 Listeners
Short Wave
6,580 Listeners
BioCentury This Week
34 Listeners
Biotech Hangout
21 Listeners